• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Down 100 Points; US Manufacturing PMI Falls In December

    1/2/24 9:53:55 AM ET
    $AVXL
    $HLTH
    $LBPH
    $LMDX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVXL alert in real time by email

    U.S. stocks traded lower this morning, with the Dow Jones index falling more than 100 points on Tuesday.

    Following the market opening Tuesday, the Dow traded down 0.28% to 37,584.41 while the NASDAQ fell 1.35% to 14,808.88. The S&P 500 also fell, dropping, 0.72% to 4,735.41.

    Check This Out: How To Earn $500 A Month From Annaly Capital Management Stock

     

    Leading and Lagging Sectors

     

    Energy shares rose by 1.1% on Tuesday.

    In trading on Tuesday, information technology shares fell by 1.8%.


    Top Headline

     

    The S&P Global manufacturing PMI was revised lower to 47.9 in December versus a preliminary level of 48.2, and versus November’s level of 49.4.

     

    Equities Trading UP

     

    Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) shares shot up 198% to $17.95 after the company announced topline data from the PACIFIC Study evaluating bexicaserin in patients with Developmental and Epileptic Encephalopathies.

    Shares of Cue Health Inc. (NASDAQ:HLTH) got a boost, surging 42% to $0.2301 after falling 42% on Friday.

    Soligenix, Inc. (NASDAQ:SNGX) shares were also up, gaining 36% to $1.0300.
    Soligenix announced publication demonstrating complete protection against filovirus disease in nonhuman primate models of ebola and marburg viruses.

     

    Equities Trading DOWN

     

    Anavex Life Sciences Corp. (NASDAQ:AVXL) shares dropped 32% to $6.31 after the company provided an update on Rett Syndrome program.

    Shares of LumiraDx Limited (NASDAQ:LMDX) were down 34% to $0.0428. LumiraDx agreed to sell its point-of-care technology platform to Roche.

    China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was down, falling 29% to $2.82 after gaining 92% on Friday.

    Also Check This Out: Top 4 Tech And Telecom Stocks That May Fall Off A Cliff In Q4

     

    Commodities

     

    In commodity news, oil traded up 0.1% to $71.72 while gold traded up 0.3% at $2,078.40.

    Silver traded up 0.5% to $24.205 on Tuesday while copper fell 0.6% to $3.8665.

     

    Euro zone

     

    European shares were mostly higher today. The eurozone’s STOXX 600 fell 0.3%, London’s FTSE 100 fell 0.4% while Spain’s IBEX 35 Index rose 0.6% The German DAX fell 0.1% French CAC 40 fell 0.5% while Italy’s FTSE MIB Index rose 0.3%.

    Bank lending to households in the Eurozone increased by 0.5% year-over-year to EUR 6.87 trillion in November. The HCOB Eurozone manufacturing PMI rose to 44.4 in December, from the preliminary level of 44.2.

    The S&P Global UK manufacturing PMI was revised lower to 46.2 in December from the preliminary estimate of 46.4, while German manufacturing PMI was revised higher to 43.3 in December versus a preliminary reading of 43.1. The HCOB France manufacturing PMI declined to 42.1 in December versus 42.9 a month ago.

     

    Asia Pacific Markets

     

    Asian markets closed lower on Tuesday, with Hong Kong’s Hang Seng Index falling 1.52% and China’s Shanghai Composite Index falling 0.43%. India’s S&P BSE Sensex, meanwhile, fell 0.53%.

    The official NBS non-manufacturing PMI for China rose to 50.4 in December from November's reading of 50.2, while manufacturing PMI fell to 49.0 in from 49.4. Singapore’s GDP increased by 2.8% year-over-year in the fourth quarter versus a revised 1.0% increase in the third quarter. The Judo Bank Australia manufacturing PMI fell to 47.6 in December versus a preliminary reading of 47.8.

     

    Economics

     

    The S&P Global manufacturing PMI was revised lower to 47.9 in December versus a preliminary level of 48.2, and versus November’s level of 49.4.

    Now Read This: Accenture, Lyft And 2 Other Stocks Insiders Are Selling

     

    Get the next $AVXL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVXL
    $HLTH
    $LBPH
    $LMDX

    CompanyDatePrice TargetRatingAnalyst
    Longboard Pharmaceuticals Inc.
    $LBPH
    9/10/2024$60.00Buy
    Truist
    Longboard Pharmaceuticals Inc.
    $LBPH
    7/1/2024$60.00 → $90.00Overweight
    Cantor Fitzgerald
    Longboard Pharmaceuticals Inc.
    $LBPH
    5/1/2024$36.00Outperform
    Robert W. Baird
    Cue Health Inc.
    $HLTH
    3/14/2024Buy → Neutral
    BTIG Research
    Longboard Pharmaceuticals Inc.
    $LBPH
    2/16/2024$40.00Buy
    Citigroup
    Longboard Pharmaceuticals Inc.
    $LBPH
    10/24/2023$16.00 → $35.00Overweight
    Cantor Fitzgerald
    Longboard Pharmaceuticals Inc.
    $LBPH
    4/27/2023$13.00Buy
    B. Riley Securities
    Anavex Life Sciences Corp.
    $AVXL
    12/6/2022$16.00 → $11.00Overweight → Neutral
    Cantor Fitzgerald
    More analyst ratings

    $AVXL
    $HLTH
    $LBPH
    $LMDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVXL
    $HLTH
    $LBPH
    $LMDX
    SEC Filings

    View All

    SEC Form 424B5 filed by China SXT Pharmaceuticals Inc.

    424B5 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)

    4/9/26 9:00:41 AM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by China SXT Pharmaceuticals Inc.

    6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)

    4/9/26 9:00:31 AM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Soligenix Inc.

    EFFECT - SOLIGENIX, INC. (0000812796) (Filer)

    4/3/26 12:15:07 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVXL
    $HLTH
    $LBPH
    $LMDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN, CEO AND PRESIDENT Schaber Christopher J bought $20,000 worth of shares (15,132 units at $1.32), increasing direct ownership by 3,993% to 15,511 units (SEC Form 4)

    4 - SOLIGENIX, INC. (0000812796) (Issuer)

    10/3/25 1:18:09 PM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CMO Kaye Randall bought $2,482 worth of shares (100 units at $24.82), sold $580,891 worth of shares (16,767 units at $34.64) and exercised 16,667 shares at a strike of $4.35 (SEC Form 4)

    4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

    8/13/24 6:01:53 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Donhauser Peter D.O. bought $10,319 worth of shares (2,835 units at $3.64), increasing direct ownership by 131% to 5,000 units (SEC Form 4)

    4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)

    6/17/24 7:30:10 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVXL
    $HLTH
    $LBPH
    $LMDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's Disease

    Findings underpin the scientific rationale for Anavex's targeted autophagy approach with orally administered blarcamesine Convergence of impaired autophagy and synaptic dysfunction across neurodevelopmental and neurodegenerative conditions aligns with blarcamesine's mechanism of action These findings support Anavex's intent to advance blarcamesine into pivotal clinical studies to further evaluate its potential in addressing unexpectedly common CNS disease mechanisms NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's diseas

    4/14/26 7:30:00 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference

    NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 25th Annual Needham Virtual Healthcare Conference, April 13 – 16, 2026. President and Chief Executive Officer Christopher U. Missling, PhD and his management team will present the Company scheduled at 1:30 PM (ET) on Tuesday, April 14th, 2026. A live audio

    4/7/26 7:30:00 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

    HyBryte™ demonstrates more rapid and robust treatment response compared toValchlor® during 12-week treatment coursePRINCETON, N.J., April 2, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the positive results of its comparability study evaluating HyBryte™ (synthetic hypericin) versus Valchlor® (mechlorethamine) for the treatment of cutaneous T-cell lymphoma (CTCL) have been published in Oncology and Therapy. 

    4/2/26 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVXL
    $HLTH
    $LBPH
    $LMDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Longboard Pharmaceuticals with a new price target

    Truist initiated coverage of Longboard Pharmaceuticals with a rating of Buy and set a new price target of $60.00

    9/10/24 7:53:02 AM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald reiterated coverage on Longboard Pharmaceuticals with a new price target

    Cantor Fitzgerald reiterated coverage of Longboard Pharmaceuticals with a rating of Overweight and set a new price target of $90.00 from $60.00 previously

    7/1/24 12:54:07 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Robert W. Baird initiated coverage on Longboard Pharmaceuticals with a new price target

    Robert W. Baird initiated coverage of Longboard Pharmaceuticals with a rating of Outperform and set a new price target of $36.00

    5/1/24 6:27:25 AM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVXL
    $HLTH
    $LBPH
    $LMDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President and CEO Missling Christopher U

    4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)

    1/9/26 5:27:25 PM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by PFO & Treasurer Boenisch Sandra

    4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)

    1/9/26 5:26:26 PM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by CMO (Consulting) Straube Richard

    4 - SOLIGENIX, INC. (0000812796) (Issuer)

    12/12/25 4:18:31 PM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVXL
    $HLTH
    $LBPH
    $LMDX
    Financials

    Live finance-specific insights

    View All

    Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update

    Company to host a webcast today at 8:30 am Eastern Time NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported financial results for its first quarter of fiscal 2026. "As we have entered 2026, we continue to progress our innovative clinical pipeline with particular focus on our lead candidate, oral blarcamesine in early Alzheimer's disease

    2/9/26 7:30:00 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026

    NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its first quarter of fiscal 2026 on Monday, February 9, 2026. Management will host a conference call on Monday February 9, at 8:30 am ET to review financial results and discuss recent corporate developments. Following management's remarks, there

    2/3/26 7:30:00 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

    Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported financial results for its fourth quarter of fiscal 2025. "There are currently an estimated 7.2 million people living with Alzheimer's disease in the U.S. and 7 million in Europe, respectively. We continue to be focused on orally

    11/25/25 7:30:00 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVXL
    $HLTH
    $LBPH
    $LMDX
    Leadership Updates

    Live Leadership Updates

    View All

    Sensorion Reports Full-Year 2025 Results, Provides Corporate Update and Announces Release of Annual Report

    GJB2-GT (SENS-601) CTA/IND-enabling studies progress, supported by regulatory interactions with FDA and EMA since Q3 2025, and on track for CTA submission in H1 2026 SENS-501 Audiogene trial ongoing; six-month efficacy data expected in Q1 2026 Strengthened balance sheet and shareholder registry via €60m financing in January 2026, including a €20m strategic investment from Sanofi; cash runway extended to end of H1 2027 Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reported its full-year 2025 results, provided a corp

    3/18/26 2:30:00 AM ET
    $LBPH
    $ARNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors

    NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Dr. Axel Paeger, MD, MBA, MBI to its Board of Directors. "We are delighted to welcome Dr. Paeger to our Board of Directors at Anavex," said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. "Dr. Paeger brings three decades of strong leade

    2/23/26 7:30:00 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology

    NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head of Neurology. Dr. Liedtke is a board-certified neurologist, who brings more than 25 years of extensive experience in developing and delivering innovative medicines in a broad range of CNS diseases, inclu

    1/8/26 7:30:00 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVXL
    $HLTH
    $LBPH
    $LMDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Longboard Pharmaceuticals Inc.

    SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)

    11/14/24 3:10:34 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Longboard Pharmaceuticals Inc.

    SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)

    11/14/24 1:22:40 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Longboard Pharmaceuticals Inc.

    SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)

    11/12/24 3:59:14 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care